TABLE 3.
Changes in outcome in the treatment group (n = 44) and placebo group (n = 32) based on the BMI status.a
| Variables | Groups | BMI status | Before intervention, median (IQR) | After intervention, median (IQR) | P-valueb |
| ALT (IU/L) | Sitagliptin | Normal | 63 (40, 74) | 41 (26, 52) | 0.59 |
| Overweight | 42 (34, 54) | 40 (24, 50) | 0.16 | ||
| Obese | 47 (35, 71) | 38 (24, 55) | 0.26 | ||
| Placebo | Normal | 56 (50, 61) | 42 (38, 46) | 0.25 | |
| Overweight | 40 (34, 68) | 34 (30, 50) | 0.48 | ||
| Obese | 33 (30, 46) | 32 (22, 53) | 0.45 | ||
| AST (IU/L) | Sitagliptin | Normal | 43 (28, 61) | 31 (21, 51) | 0.58 |
| Overweight | 32 (28, 44) | 24 (20, 37) | 0.028 | ||
| Obese | 39 (29, 44) | 24 (17, 33) | 0.016 | ||
| Placebo | Normal | 42 (37.5, 43.0) | 29 (28.0, 36.5) | 0.50 | |
| Overweight | 30 (28, 47) | 26 (20, 31) | 0.055 | ||
| Obese | 27 (26, 34) | 22 (17, 28) | 0.38 | ||
| GGT (IU/L) | Sitagliptin | Normal | 62 (57, 66) | 51 (42, 64) | 0.62 |
| Overweight | 41 (35, 52) | 41 (37, 44) | 0.66 | ||
| Obese | 42 (36, 51) | 42 (40, 46) | 0.85 | ||
| Placebo | Normal | 46 (43.50, 48.50) | 48 (45.00, 49.00) | > 0.99 | |
| Overweight | 35 (20, 49) | 38 (29, 43) | > 0.99 | ||
| Obese | 41 (30, 52) | 41 (40, 47) | > 0.99 | ||
| ALKP (IU/L) | Sitagliptin | Normal | 207 (164, 270) | 164 (146, 195) | 0.062 |
| Overweight | 198 (155, 205) | 175 (159, 208) | 0.42 | ||
| Obese | 212 (156, 228) | 213 (155, 256) | 0.17 | ||
| Placebo | Normal | 176 (139, 180) | 195 (151, 196) | 0.25 | |
| Overweight | 170 (160, 211) | 179 (168, 198) | 0.35 | ||
| Obese | 184 (158, 244) | 177 (175, 205) | > 0.99 | ||
| Fibro score | Sitagliptin | Normal | 7.05 (6.05, 8.72) | 5.45 (5.18, 7.75) | 0.036 |
| Overweight | 6.15 (5.82, 7.15) | 5.55 (5.00, 6.27) | 0.018 | ||
| Obese | 6.45 (6.00, 7.08) | 6.00 (5.70, 6.85) | 0.24 | ||
| Placebo | Normal | 4.60 (4.60, 6.30) | 6.60 (5.30, 6.70) | > 0.99 | |
| Overweight | 5.50 (5.00, 6.07) | 5.25 (4.73, 6.00) | 0.67 | ||
| Obese | 6.90 (6.20, 7.10) | 5.50 (5.00, 7.00) | 0.10 |
aMedian (IQR).
bWilcoxon signed rank test with continuity correction; Wilcoxon signed rank exact test.